article thumbnail

Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More

Xconomy

Then came the rumor mill: Companies may or may not be approaching Biogen about a sale, and Biogen may or may not be fielding offers. —Immunotherapy news: Menlo Park, CA-based Adicet Bio struck a five-year deal with Regeneron Pharmaceuticals (NASDAQ: REGN ) to make “off the shelf” T cell treatments for various cancers.

News 40
article thumbnail

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

Xconomy

The deal also includes a $175 million deferred payment due in 2019 and $850 million in downstream payouts tied to regulatory and sales targets. Two days later, it paid AstraZeneca $550 million upfront for the rights to a group of antibiotics either already on the market or in late-stage testing.

Pricing 40